S2R
0.13
38.3%
XGLR
0.004
-42.9%
4DX
0.775
36%
ALM
0.005
-28.6%
8CO
0.035
34.6%
MEM
0.003
-25%
AUK
0.004
33.3%
TYX
0.003
-25%
AYT
0.004
33.3%
OMG
0.011
-21.4%
BLU
0.008
33.3%
OEL
0.004
-20%
DRE
0.016
33.3%
PKD
0.028
-17.6%
FRX
0.008
33.3%
BRU
0.02
-16.7%
JAL
0.12
30.4%
ETM
0.07
-16.7%
ILT
0.275
27.9%
OSX
0.01
-16.7%
AHK
0.435
26.1%
TAR
0.01
-16.7%
RUL
4.63
22.8%
IFG
0.031
-16.2%
AGD
0.049
22.5%
DEL
0.13
-16.1%
AZI
0.023
21.1%
TG1
0.028
-15.2%
DAL
0.047
20.5%
AVE
0.006
-14.3%
AHN
0.006
20%
AZL
0.006
-14.3%
AKN
0.006
20%
ENV
0.006
-14.3%
ARV
0.006
20%
LCL
0.006
-14.3%
KAL
0.048
20%
SPX
0.006
-14.3%
MGU
0.012
20%
VHL
0.025
-13.8%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

AGN on track for Phase 2 trials during CY24

Argenica Therapeutics (ASX:AGN) has completed the manufacturing of the ARG-007 drug required for Phase 2 clinical trials. The finalised, sterile drug product manufacturing will be completed by the end of the year keeping the Argenica on track for first patient dosing during Q1 CY24 | ASX Announcement: https://announcements.asx.com.au/asxpdf/20231214/pdf/05yjzbqmnd1b00.pdf $AGN #Phase2 #ClinicalTrials #shorts